MedTrace Logo

Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation

NCT00143117 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2012-11-07

No results posted yet for this study

Summary

To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.

Conditions

  • Ejaculation

Interventions

DRUG

UK-390,957

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143117 on ClinicalTrials.gov